Treatment of polymicrobial intra-abdominal pelvic, and diabetic foot infections

Comprehensive Therapy

Volumn 24, Issue 6-7, 1998, Pages 295-301

  Zervos, Marcus ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; DIABETIC FOOT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; PELVIC INFLAMMATORY DISEASE; REVIEW;

EID: 0031831557     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Southern PM. Antibiotics update. Compr Ther. 1997;23:575-582.
2. Shands JW Jr. Empiric antibiotic therapy of abdominal sepsis and serious perioperative infections. Surg Clin North Am. 1993;73:291-306.
3. Grayson ML. Diabetic foot infections: antimicrobial therapy. Infect Dis Clin North Am. 1995;9:143-161.
4. Vemuri RK, Zervos MJ. Enterococcal infections: the increasing threat of nosocomial spread and drug resistance. Postgrad Med. 1993;93:121-128.
5. Zervos MJ, Dembry L. Enterococcus in surgical infections: virulence, epidemiology, and resistance. Infect Dis Clin Pract. 1994;3(suppl 1):S14-S20.
6. Seabrook GR, Edmiston CE, Schmitt DD, Krepel C, Bandyk DF, Towne JB. Comparison of serum and tissue antibiotic levels in diabetes-related foot infections. Surgery. 1991;110: 671-677.
7. MacLaren DM, Namavar F, Verweij-van Vught AMJJ, Vel WAC, Kaan JA. Pathogenic synergy: mixed intra-abdominal infections. Antonie van Leeuwenhoek. 1984;50:775-787.
8. Wilson SE, Nord CE. Clinical trials of extended spectrum penicillin/beta-lactamase inhibitors in the treatment of intra-abdominal infections: European and North American experience. Am J Surg. 1995;169(suppl 5A):21S-26S.
9. Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a ß-lactamase inhibitor combination for serious intra-abdominal infections. Ann Surg. 1993;217:115-121.
10. Christou NV, Turgeon P, Wassef R, et al. Management of intra-abdominal infections: the case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. Arch Surg. 1996;131:1193-1201.
11. Stone HH. Bacterial flora of appendicitis in children. J Pediatr Surg. 1976;11:37-42.
12. Thadepalli H, Reddy U, Chuah SK, et al. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother. 1997;41:583-586.
13. Aldridge KE, Ashcraft D, Bowman KA. Comparative in vitro activities of trovafloxacin (CP-99,219) and other antimicrobials against clinically significant anaerobes. Antimicrob Agents Chemother. 1997;41:484-487.
14. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis. 1996;15:913-921.
15. Welton L, Zervos MJ. Commentary: vancomycin-resistant enterococci. Infect Dis Clin Pract. 1996;5:535-537.
16. Hemsell DL. Sulbactam/ampicillin for treatment of polymicrobial pelvic infections. Drugs. 1986;31(suppl 2):22-25.
17. Wexler HM, Harris B, Carter WT, Feingold SM. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria. Antimicrob Agents Chemother. 1985;27: 876-878.
18. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg. 1990;212:581-591.
19. Hart SM, Bailey EM. A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations. Ann Pharmacother. 1996;30:1130-1140.
20. Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Agents Chemother. 1997;41:2312-2316.
21. Data on file. Pfizer Inc, New York, NY.
22. Sweet RL. Pelvic inflammatory disease. Hosp Pract. 1993;28 (suppl 2):25-30.
23. Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease: trends and projections, 1983 through 2000. JAMA 1991;266:2565-2573.
24. Creatsas GK, Pavlatos MP, Koumantakis E, Zolotas J, Kaskarelis DB. Bacteriologic aspects of pelvic inflammatory disease in gynecologic patients. Gynecol Obstet Invest. 1982; 13:1-8.
25. Louria DB, Sen P. Anaerobic infections of the pelvis. Obstet Gynecol 1980;55(suppl):114S-120S.
26. Ohm-Smith MJ, Hadley WK, Sweet RL. In vitro activity of new ß-lactam antibiotics and other antimicrobial drugs against anaerobic isolates from obstetric and gynecological infections. Antimicrob Agents Chemother. 1982;22:711-714.
27. Finegold SM. Management of anaerobic infections. Ann Intern Med. 1975;83:375-383.
28. Centers for Disease Control. Sexually transmitted diseases treatment guidelines. MMWR. 1998;47:1-116.
29. Campoli-Richards DM, Brogden RN. Sulbactam/ampicillin: a review of its antibacterial activity, pbarmacokinetic properties, and therapeutic use. Drugs. 1987;33:577-609.
30. Schwiersch U, Lang N, Wildfeuer DA. Concentration of sulbactam and ampicillin in serum and the myometrium. Drugs. 1986;31(suppl 2):26-28.
31. Giamareliou H, Trouvas G, Avlami A, Aravantinos D, Daikos GK. Efficacy of sulbactam plus ampicillin in gynecologic infections. Rev Infect Dis. 1986;8(suppl 5):S479-S482.
32. Crombleholme W, Landers D, Ohm-Smith M, et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs. 1986;31(suppl 2):11-13.
33. Crombleholme WR, Ohm-Smith M, Robbie MO, DeKay V, Sweet RL. Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. Am J Obstet Gynecol 1987;156:507-513.
34. Abbassi AF, Said A, Gaber A. Intramuscular sulbactam/ ampicillin combination therapy in gynaecological and obstetric bacterial infections. J Int Med Res. 1991;19(suppl 1):44A-49A.
35. Haria M, Lamb HM. Trovafloxacin. Drugs. 1997;54:435-445.
36. Jones RB, Van der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):63-65.
37. Report of the National Commission on Diabetes. Washington, DC: US Dept of Health, Education, and Welfare; 1976. Publication NIH 76-1022.
38. Fierer J, Daniel D, Davis C. The fetid foot: lower extremity infections in patients with diabetes mellitus. Rev Infect Dis. 1979;1:210-217.
39. Wheat LJ, Alien SD, Henry M, et al. Diabetic foot infections: bacteriologic analysis. Arch Intern Med. 1986;146: 1935-1940.
40. Goldstein EJC, Citron DM, Nesbit CA. Diabetic foot infections: bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care. 1996;19:638-641.
41. Asfar SK, Al-Arouj, M, Al-Nakhi A, Baraka A, Juma T, Johny M. Foot infections in diabetics: the antibiotic choice. JCC. 1993;36:170-172.
42. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994;18:683-693.
43. McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1997;24:57-63.